Jun 2026 (Q2 FY26) — Aug 11, 2026
NeuroPace Q2 FY26 — Strong Core RNS Growth Amidst IGE Regulatory Setback
Read the full callNeuroPace (NPCE) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
NeuroPace earnings: last reported Tue, 11 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 22.8 | +17.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -22.5 | +19.5 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -6.2 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$12.77 +4.33% · +$0.53
Performance +22.7% 1Y
1Y: $10.41 on 17 Oct 2025 → $12.77. High $19.29 (7 May 2026), low $9.4 (3 Nov 2025).
- Previous close
- $12.24
- 52-week range
- $9.4 – $19.29
- One year
- +18.90%
Overview
- Symbol
- NPCE
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
NeuroPace earnings calls (NPCE)
Financials
What the filings say
Net profit, year on year: +28% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 21 | 21 | 23 | 20 | 27 | 27 | 22 | 23 |
| Operating profit | -4 | -4 | -5 | -8 | -3 | -2 | -6 | -5 |
| Operating margin | −20.1% | −17.0% | −22.9% | −42.0% | −9.5% | −6.7% | −25.2% | −22.5% |
| Interest | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Net profit | -5 | -5 | -7 | -9 | -3 | -3 | -7 | -6 |
| EPS ($ per share) | -0.19 | — | -0.21 | -0.26 | -0.11 | — | -0.20 | -0.18 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -388 | -424 | -471 | -504 | -531 | -552 |
| Total liabilities | 62 | 60 | 79 | 87 | 87 | 87 |
| Fixed assets | 1 | 1 | 1 | 1 | 1 | 1 |
| Investments | 12 | 96 | 71 | 48 | 39 | 39 |
| Total assets | 56 | 134 | 114 | 108 | 95 | 106 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Cash from operations | -22 | -25 | -37 | -20 | -18 | -11 |
| Cash from investing | -11 | -85 | 24 | 23 | 9 | -0 |
| Cash from financing | 55 | 103 | 0 | 8 | 4 | 20 |
| Net cash flow | 23 | -7 | -13 | 11 | -5 | 8 |
| Capital expenditure | -0 | -0 | -1 | -0 | -0 | -0 |
| Free cash flow | -22 | -25 | -37 | -20 | -18 | -11 |
Insider filings
40 filings between Nov 20, 2025 and Sep 24, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$399.3K
1 sale by 1 insider
Compensation
not trading decisions- 20
- Award — granted as compensation
- 19
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Morrell Martha | — | $399.3K | Dec 15, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 24, 2026 | Morrell Martha CHIEF MEDICAL OFFICER | Tax withheld | 335 | $4.7K |
| Sep 20, 2026 | Williams Patrick F. Chief Financial Officer | Tax withheld | 1,162 | $16.6K |
| Sep 3, 2026 | Becker Joel CHIEF EXECUTIVE OFFICER | Tax withheld | 1,310 | $19.3K |
| Aug 27, 2026 | Becker Joel CHIEF EXECUTIVE OFFICER | Tax withheld | 1,126 | $15.9K |
| Aug 27, 2026 | Morrell Martha CHIEF MEDICAL OFFICER | Tax withheld | 358 | $5.1K |
| Jun 24, 2026 | Morrell Martha CHIEF MEDICAL OFFICER | Tax withheld | 335 | $5.4K |
| Jun 19, 2026 | Geiger Uri Director | Award | 789 | $12.3K |
| Jun 19, 2026 | Kumar Rakhi Director | Award | 989 | $15.5K |
| Jun 19, 2026 | Fischer Frank M Director | Award | 1,467 | $22.9K |
| Jun 5, 2026 | Fischer Frank M Director | Award | 2,890 | $0 |
| Jun 5, 2026 | Ryan Renee Director | Award | 2,890 | $0 |
| Jun 5, 2026 | Huennekens R Scott Director | Award | 2,890 | $0 |
| Jun 5, 2026 | Geiger Uri Director | Award | 2,890 | $0 |
| Jun 5, 2026 | Andrade Lisa Director | Award | 2,890 | $0 |
| Jun 5, 2026 | Kumar Rakhi Director | Award | 2,890 | $0 |
| Jun 3, 2026 | Becker Joel CHIEF EXECUTIVE OFFICER | Tax withheld | 1,255 | $19.9K |
| May 27, 2026 | Morrell Martha CHIEF MEDICAL OFFICER | Tax withheld | 358 | $6.1K |
| May 27, 2026 | Becker Joel CHIEF EXECUTIVE OFFICER | Tax withheld | 1,126 | $19.2K |
| May 15, 2026 | Williams Patrick F. Chief Financial Officer | Award | 16,820 | $0 |
| May 15, 2026 | Morrell Martha CHIEF MEDICAL OFFICER | Award | 5,460 | $0 |
| May 15, 2026 | Becker Joel CHIEF EXECUTIVE OFFICER | Award | 45,880 | $0 |
| Mar 24, 2026 | Morrell Martha CHIEF MEDICAL OFFICER | Tax withheld | 1,341 | $17.8K |
| Mar 20, 2026 | LACOB JOSEPH Director | Award | 865 | $11.2K |
| Mar 20, 2026 | Geiger Uri Director | Award | 913 | $11.9K |
| Mar 20, 2026 | Kumar Rakhi Director | Award | 1,153 | $15.0K |
| Mar 20, 2026 | Fischer Frank M Director | Award | 1,826 | $23.7K |
| Mar 3, 2026 | Becker Joel CHIEF EXECUTIVE OFFICER | Tax withheld | 5,023 | $69.5K |
| Mar 3, 2026 | Morrell Martha CHIEF MEDICAL OFFICER | Tax withheld | 1,340 | $18.5K |
| Feb 27, 2026 | Morrell Martha CHIEF MEDICAL OFFICER | Tax withheld | 358 | $5.2K |
| Feb 27, 2026 | Becker Joel CHIEF EXECUTIVE OFFICER | Tax withheld | 1,126 | $16.4K |
| Feb 20, 2026 | Morrell Martha CHIEF MEDICAL OFFICER | Tax withheld | 3,412 | $48.9K |
| Dec 19, 2025 | Kumar Rakhi Director | Award | 904 | $15.0K |
| Dec 19, 2025 | Geiger Uri Director | Award | 715 | $11.9K |
| Dec 19, 2025 | Fischer Frank M Director | Award | 1,431 | $23.7K |
| Dec 19, 2025 | LACOB JOSEPH Director | Award | 678 | $11.2K |
| Dec 15, 2025 | Morrell Martha CHIEF MEDICAL OFFICER | Sale | 25,000 | $399.3K |
| Dec 3, 2025 | Morrell Martha CHIEF MEDICAL OFFICER | Tax withheld | 1,338 | $22.3K |
| Nov 27, 2025 | Becker Joel CHIEF EXECUTIVE OFFICER | Tax withheld | 1,126 | $18.6K |
| Nov 27, 2025 | Morrell Martha CHIEF MEDICAL OFFICER | Tax withheld | 357 | $5.9K |
| Nov 20, 2025 | Morrell Martha CHIEF MEDICAL OFFICER | Tax withheld | 3,051 | $41.2K |
| Sep 19, 2025 | Fischer Frank M Director | Award | 2,389 | $23.7K |
| Sep 19, 2025 | LACOB JOSEPH Director | Award | 1,131 | $11.2K |
| Sep 19, 2025 | Kumar Rakhi Director | Award | 1,509 | $15.0K |
| Sep 19, 2025 | Geiger Uri Director | Award | 1,194 | $11.9K |
| Sep 3, 2025 | Morrell Martha CHIEF MEDICAL OFFICER | Tax withheld | 1,337 | $12.5K |
| Aug 27, 2025 | Becker Joel CHIEF EXECUTIVE OFFICER | Tax withheld | 1,126 | $10.0K |
| Aug 27, 2025 | Morrell Martha CHIEF MEDICAL OFFICER | Tax withheld | 357 | $3.2K |
| Aug 20, 2025 | Morrell Martha CHIEF MEDICAL OFFICER | Tax withheld | 3,052 | $26.4K |
| Jun 21, 2025 | Kumar Rakhi Director | Award | 1,440 | $15.0K |
| Jun 21, 2025 | LACOB JOSEPH Director | Award | 1,080 | $11.2K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for NeuroPace Inc
Free account. Everything above stays public.
Write why you follow NeuroPace Inc and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading